Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Instituto Butantan has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units. GRASER, JENNIFER E is the busiest examiner, with 1 pending matter, indicating separate examination channels for the current cases.
Counsel should preserve a consistent scientific narrative while preparing distinct responses for each application. The absence of a repeated examiner or art unit means that no single prosecution relationship controls the docket. Effective management will depend on tracking each action separately and tying any claim amendment closely to the relevant technical disclosure.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRASER, JENNIFER E | 1 | 76.8% | +23.2% |
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837804 | COMPOSITIONS COMPRISING RECOMBINANT STRAINS OF MYCOBACTERIUM, USES THEREOF AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF CANCER | GRASER, JENNIFER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782899 | PROCESS FOR PRODUCING A PROPHYLACTIC AND THERAPEUTIC DNA IMMUNOLOGICAL COMPOSITION FOR HPV AND CANCERS ASSOCIATED WITH THE VIRUS, HYBRID PROTEIN, EXPRESSION VECTOR, IMMUNOLOGICAL COMPOSITION AND USES THEREOF | JADHAO, SAMADHAN JAISING | 25d overdue |
| 18837804 | COMPOSITIONS COMPRISING RECOMBINANT STRAINS OF MYCOBACTERIUM, USES THEREOF AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF CANCER | GRASER, JENNIFER E | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837804 | COMPOSITIONS COMPRISING RECOMBINANT STRAINS OF MYCOBACTERIUM, USES THEREOF AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF CANCER | GRASER, JENNIFER E | 1645 | §103§112 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 17782899 | PROCESS FOR PRODUCING A PROPHYLACTIC AND THERAPEUTIC DNA IMMUNOLOGICAL COMPOSITION FOR HPV AND CANCERS ASSOCIATED WITH THE VIRUS, HYBRID PROTEIN, EXPRESSION VECTOR, IMMUNOLOGICAL COMPOSITION AND USES THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §112 | Final Rejection | 25d overdue | Pending | Jun 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstituto Butantan has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jennifer E Graser has the most, with 1 of Instituto Butantan's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
